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Vaccine reverse-engineeringVaccine reverse engineering is emerging as an important approach to vaccine antigen identiﬁcation, recently
focusing mainly on structural characterization of interactions between neutralizing monoclonal antibodies
(mAbs) and antigens. Using mAbs that bind unknown antigen structures, we sought to probe the intrinsic
features of antibody antigen-binding sites with a high complexity peptide library, aiming to identify
conformationally optimized mimotope antigens that capture mAb-speciﬁc epitopes. Using a high throughput
sequencing-enhanced messenger ribonucleic acid (mRNA) display approach, we identiﬁed high afﬁnity binding
peptides for a hepatitis C virus neutralizing mAb. Immunization with the selected peptides induced neutralizing
activity similar to that of the original mAb. Antibodies elicited by the most commonly selected peptides were
predominantly against speciﬁc epitopes. Thus, using mRNA display to interrogate mAbs permits high resolution
identiﬁcation of functional peptide antigens that direct targeted immune responses, supporting its use in vaccine
reverse engineering for pathogens against which potent neutralizing mAbs are available.
Research in Context: We used a large number of randomly produced small proteins (“peptides”) to identify
peptides containing speciﬁc protein sequences that bind efﬁciently to an antibody that can prevent hepatitis
C virus infection in cell culture. After the identiﬁed peptides were injected into mice, the mice produced their
own antibodies with characteristics similar to the original antibody. This approach can provide previously
unavailable information about antibody binding and could also be useful in developing new vaccines.
© 2015 Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
As evidenced by the isolation and cloning of neutralizing monoclo-
nal antibodies (mAbs) against pathogens like hepatitis C virus (HCV)
and human immunodeﬁciency virus (HIV) for which licensed vaccines
are not available, humans are capable of producing such antibodies
(Sautto et al., 2013; Mascola and Haynes, 2013), but identiﬁcation of
these natural mAbs has not yet led to successful vaccine antigen design.
Traditional approaches using whole pathogens (live, attenuated or
inactivated) or subunit vaccines do not always induce the desired
neutralizing antibodies. Identiﬁcation of antigens that can induce
humoral responses that mimic neutralizing mAbs would be very useful
in developing improved vaccine strategies. Such antigens could be
considered as priming vaccines (providing “original antigenic sin” that
directs the immune response after subsequent exposures towards
induction of desired neutralizing antibodies) or as components of3234 HFM-457, 10903 New
e).
en access article under the CC BY licmultivalent vaccines (which could potentially induce immune re-
sponses against multiple neutralizing epitopes).
“Vaccine reverse engineering” (Burton, 2002) focuses on inferring the
structure of improved immunogens based on interactions with neutralizing
antibodies. While “epitope focused antigen design” (Correia et al., 2014)
and other structural approaches (Kulp and Schief, 2013) show promise in
identifying the three dimensional structure of antigens that could elicit
mAb-like neutralizing responses, it also is recognized that the link between
physical structure and landscapes recognized by mAbs can be analyzed
using antigenic approaches (Dormitzer et al., 2008) that examine the binding
speciﬁcity of mAbs. For the many neutralizing mAbs with unknown three-
dimensional structures of antigen-antibody complexes, identiﬁcation of
antigens that can optimally present the critical epitopes to the immune
system remains a challenge. We reasoned that a given mAb could be
antigenically characterized by identifying a series of tightly binding
antigens that, collectively and uniquely deﬁne the binding speciﬁcity of
the antibody, and thus exploredwhether probing neutralizing antibodies
with a high-complexity random peptide library could allow identiﬁca-
tion of optimized antigens that capture key information about a mAb
of interest, holding the potential to generate immune responses that
have properties similar to that of the mAb.ense (http://creativecommons.org/licenses/by/4.0/).
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messenger ribonucleic acid (mRNA) display, which generates random
peptide libraries with complexity as high as N1013 unique sequences
(Takahashi et al., 2003). Each peptide is covalently bound to its
encoding mRNA through a puromycin linkage, enabling in vitro selec-
tion of peptide libraries (ranging from 1 to over 100 amino acids) that
bind to targets of interest (including antibodies) and the use of reverse
transcriptase polymerase chain reaction (RT-PCR) and sequencing to
determine the nucleic acid sequence corresponding to the peptides
that bind the target. The high library complexity ofmRNAdisplay allows
selection of extremely rare and high afﬁnity binding partners, and its
use in epitope mapping has been described (Baggio et al., 2002; Ja
et al., 2005).
In the present study, we integratedmRNAdisplay and high through-
put sequencing (mRNA display-HTS) to identify peptide mimotopes
that capture important information from HCV neutralizing mAb41
(Duan et al., 2012). This approach enabled high-resolution mapping of
this mAb's binding speciﬁcity. MAb41 was previously obtained from
mice immunized with a HCV genotype 1a (GT1a) wild type peptide
fragment named peptide A (pA) (Duan et al., 2012), comprising amino
acid residues 412 to 447 of the E2 protein. MAb41 neutralizes cell
culture HCV (HCVcc) in a GT1a-speciﬁc manner (Duan et al., 2012).
Using mRNA display-HTS to select for peptides that bind to mAb41,
we hoped to identify peptide mimotopes that capture key information
unique to this neutralizing antibody's antigen binding sites, potentially
identifying peptide antigens that can present mAb-speciﬁc epitopes
in an optimal context. While these peptide mimotopes likely will
have limitations as stand-alone vaccine candidates, the identiﬁed anti-
gens could potentially serve as optimized core epitope components in
the context of scaffolds or other antigen presentation strategies. We
evaluated the binding afﬁnity of the selected peptides to the original
mAb, and further investigated their ability to stimulate immune
responses.
2. Materials and Methods
2.1. mRNA Display Selection
Library construction. Sequences of the deoxyribonucleic acid (DNA)
library for mRNA display and the primers used for PCR ampliﬁcation
of the library were adopted from a previous publication (Ja and
Roberts, 2004). The sense DNA oligonucleotide, 5′-GGG ACA ATT ACT
ATT TAC AAT TAC AAT G (Trimer)15or27 CAG CTG CGT AAC TCT TGC
GCT-3′, was synthesized by the Yale Keck lab. Its sequence contains a
T7 promoter, a cytomegalovirus (CMV) translation enhancer, an ATG
start codon followed by a 15 or 27-mer random region, and a constant
3′ region encoding the peptide QLRNSCA. “Trimer” represents the
mixture of 20 trimer phosphoramidites, each representing one amino
acid (Glen Research, Sterling, VA), andwas used to increase library ran-
domness and to avoid stop codons. The sense oligo was PCR ampliﬁed 6
cycles with the following primers: sense 5′-GGA TTC TAA TAC GAC TCA
CTA TAG GGA CAA TTA CTA TTT ACA ATT AC -3′, and antisense 5′-AGC
GCA AGA GTT ACG CAG CTG-3′ to produce the initial DNA template
for in vitro transcription.
mRNA–peptide fusion synthesis. mRNA–peptide fusions were
prepared as described previously (Takahashi and Roberts, 2009) with
modiﬁcations. The PCR ampliﬁed library was transcribed in vitro using
MEGAscript Kit (Life Technologies, Grand Island, NY), and puriﬁed
using NucAway spin columns (Life Technologies). mRNA was then
ligated to a 5'-phosphorylated puromycin linker (5′-A21[S9]3ACCP in
which S9 = phosphoramidite spacer 9 (Glen Research) and P = puro-
mycin (Glen Research)) by T4 DNA ligase (Invitrogen) in the presence
of Splint (5′-TTT TTT TTT TTN AGC GCA AGA GT-3′, N = A, T, G or
C) to produce puromycin-conjugated mRNA templates. The ligated li-
brary was puriﬁed by electrophoresis through a TBE-Urea Gel (Life
Technologies) followed by extraction by electro-elution (D tube,Novagen, Madison, WI). The puriﬁed mRNA library was translated
using the Retic Lysate IVT In Vitro Translation Kit (Life Technologies).
KCl (500 mM ﬁnal) and MgCl2 (60 mM ﬁnal) were added after the
translation reaction to promote fusion formation. mRNA–peptide fu-
sionswere puriﬁed by binding to Dynabeads Oligo-[dT]25 (Life Technol-
ogies) in 100mMTris (pH 7.5), 1 M NaCl, and 0.2% Triton X-100 at 4 °C.
After washing, fusions were eluted at 65 °C with H2O. Fusions were
reverse-transcribed using SuperScript First-Strand reverse transcriptase
(Life Technologies).
Selection. After reverse-transcription, mRNA–peptide fusions were
pre-cleared three times using Dynabeads Protein G (Life Technologies).
Pre-cleared samples were then incubated with Dynabeads Protein G
coupled with monoclonal antibodies in 1× binding buffer (PBS plus
0.1% Triton), 0.5 mg/ml BSA (Life Technologies) and 1 μg/ml yeast
tRNA (Life Technologies) for 1 h at room temperature followed by
washing six times. cDNA was ampliﬁed by PCR using the sense and an-
tisense primers listed in Library construction.
2.2. High Throughput Sequencing (HTS) and Data Analysis
PCR products from the selection step were puriﬁed using Agencourt
AMPure XP beads (Beckman Coulter, Brea, CA), eluted with 10 mM Tris
(pH 7.5), and subjected to 6 cycles of PCR to add Illumina adapters with
the following primers: forward 5′-AATGAT ACGGCG ACCACCGAGATC
TAC ACT CTT TCC CTA CAC GAC GCT CTT CCG ATC TNN NNG GAT TCT
AAT ACG ACT CAC TAT AG-3′ (N = A, T, C or G), and reverse 5′-CAA
GCA GAA GAC GGC ATA CGA GAT CGT GAT GTG ACT GGA GTT CAG
ACG TGT GCT CTT CCG ATC AGC GCA AGA GTT ACG CAG CTG-3′. PCR
products were puriﬁed using Agencourt AMPure XP beads (Beckman
Coulter) and were analyzed using an Agilent 2100 Bioanalyzer. 2
nanomoles of puriﬁed PCR products were denatured and subjected to
MiSeq (Illumina, San Diego, CA) sequencing. Sequences were translated
into peptide sequences. Sequences endingwith QLRNSCAwere selected
and ranked by their copy numbers. A series of in-house Python
programs were developed for sequence analysis.
2.3. Peptides
All peptides were synthesized either by the Core Facility of
the Center for Biologics Evaluation and Research at the U.S. Food and
Drug Administration, or by United Biosystems, Inc. (Herndon, VA).
Amino acids in peptide sequences are described using single letter
codes. A slash (/) denotes the alternative use of the amino acids di-
rectly before and after the slash. In some cases, a dash (–) is intro-
duced between adjacent amino acids to simplify presentation of
alignments.
2.4. ELISA
Biotinylated peptide enzyme-linked immunosorbent assays
(ELISAs) were performed as previously described (Major et al., 1999)
using 1 μg peptide/well for coating. Speciﬁc antibodies were detected
using goat anti-mouse peroxidase-conjugated IgG (KPL, Gaithersburg,
MD) at 1 μg/ml, and the reaction was developed with ABTS peroxidase
substrate (KPL) and stopped by the addition of 1× STOP solution
(KPL). The absorbance was measured at 405 nm using a Biorad plate
reader.
2.5. Competitive ELISA
Streptavidin coated 96-well ELISA plates were coated with 1 μg/
well biotinylated peptide B as previously described (Major et al.,
1999). Equal amounts of mAb (12 ng in 100 μl PBS containing 5%
milk) were added to each well with increasing amounts of competi-
tor peptide (from 0 to 0.8 μg). After 1 hr incubation at room temper-
ature and washing, secondary antibody was added. The substrate
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Fig. 1.mRNA display selection combined with HTS. The DNA library used contains a T7
promoter (T7), a CMV Translation enhancer (TE), a 15 or 27-mer random region
((Trimer)15or27) and a constant region (3′ constant) encoding the peptide QLRNSCA.
“Trimer” represents the mixture of 20 trimer (codon) phosphoramidites (Glen Research),
each encoding one amino acid. In vitro transcription, ligation to a puromycin linker
(green), in vitro translation and reverse transcription (RT) were performed as described
in the Materials and methods section. mRNA/DNA–peptide fusions were applied to
protein G magnetic beads (ProG beads) complexed with monoclonal antibodies (mAb)
for selection. The regenerated DNA library was converted to an Illumina sequencing
library by PCR ampliﬁcation using forward and reverse primers containing Illumina
adapters and subjected to MiSeq sequencing.
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2.6. Afﬁnity Measurements by Octet
Binding kinetics of mAb41 Fab to selected peptides were measured
using a Fortebio Octet Red 96 instrument (Menlo Park, CA). All assays
were performed in 1× kinetic buffer (Fortebio). Biotinylated peptides
were loaded onto streptavidin biosensors (Fortebio) for 100 s and
quenched with biocytin. A two-fold dilution series of antibody Fab
(prepared using a mouse IgG1 kit, Pierce) was used as analyte. Associa-
tion was performed for 300 s and dissociation for 900 s. Binding
constants were obtained by ﬁtting sensorgrams with a 1:1 model
using ForteBio Data Analysis Software.
2.7. Mouse Immunizations
Mice were housed and immunized in the Center for Biologics Evalu-
ation and Research (CBER) Division of Veterinary Services facilities.
Studieswere carried out in strict accordancewith the recommendations
in the Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health (NIH) and were performed under protocols
approved by the CBER Institutional Animal Care and Use Committee.
Groups (n = 4–5 animals) of ~3-month-old BALB/c mice were immu-
nized subcutaneously with 10 μg peptide emulsiﬁed in Complete
Freund's Adjuvant as well as intraperitoneally with 10 μg of peptide
formulatedwith Alum. For both routes of administration, a promiscuous
polio T-helper peptide (10 μg per mouse) (Leclerc et al., 1991) was
combined with the HCV-speciﬁc peptide to improve immunogenicity
for all immunizations. Boosts at 4 and 8 weeks were performed using
the same protocol with the exception of the use of the Incomplete
Freund's Adjuvant for subcutaneous injection. The mice were bled
14 days after the second boost, and the immunological responses
were measured as described.
2.8. Neutralization Assay
Neutralization assays were performed as previously described
(Duan et al., 2010) using cell culture HCV (HCVcc) in Huh 7.5 cells. An
HCV GT1a/2a chimeric virus was produced by replacing the structural
genes of J6/JFH1(a GT2a clone, a gift from Charles Rice at Rockefeller
University) with those of the HCV H77 (genotype 1a) strain (Kachko
et al., 2011). Virus stocks were diluted in Dulbecco modiﬁed Eagle
medium (DMEM) supplemented with 10% fetal bovine serum–1%
penicillin–streptomycin–2 mM glutamine to yield ~50–100 infectious
foci per well in the absence of antibodies. Viruses were mixed with di-
luted polyclonal serum or naïve serum, incubated at 37 °C for 1 h, and
then inoculated into Huh 7.5 cells. After 3 days in culture, virus foci
were detected either by immunoﬂuorescence or immunoperoxidase
staining (Lindenbach et al., 2005) and counted. Neutralization was
determined by comparing the infectivity of the viruses incubated with
the polyclonal serum to the infectivity of the viruses incubated with
media alone. Experimenters who performed the neutralization assay
were blinded.
2.9. Afﬁnity Depletion of Peptide-speciﬁc Antibodies
A total of 20 μg of biotinylated synthetic peptides were incubated
with 100 μl of Dynabeads M-280 Streptavidin (Life Technologies) at
room temperature for 1 h. After washing with PBS (pH 7.4), the beads
were blocked with 5% milk in phosphate-buffered saline (PBS), and
incubated with diluted polyclonal serum at room temperature for 1 h.
The beads were pelleted with a magnet stand, and the supernatant
was collected for further analysis.2.10. Statistical Analysis
Statistical analysis was performed with GraphPad Prism 6 using an
unpaired Student t test with a two-tailed p value. Error bars represent
the standard error of the mean.3. Results
3.1. Development of mRNA Display-HTS for Mimotope Identiﬁcation
To validate our experimental system, we ﬁrst performed mRNA
display selection using FLAG M2 mAb as “selection antibody” using a
15-mer library. After each round of selection, nucleic acid sequences
linked to the peptides that remained bound to the M2 mAb were PCR-
ampliﬁed and subjected to Illumina MiSeq HTS sequencing (Fig. 1).
We deduced peptide sequences from the HTS results, and ranked the
peptides by their frequency within the HTS run as a reﬂection of their
relative afﬁnity for the selection antibody. After 2 rounds of selection
with FLAG M2 mAb, the consensus motif DYKXXD homologous to the
FLAG epitope (DYKDDDDK) was readily identiﬁed among the most
frequent peptide sequences obtained (Figure S1), indicating a valid
experimental system. Consistent with a recent report (Olson et al.,
2012), these results showed that HTS provided a large number of
sequences for pattern identiﬁcation, and reduced the number of
mRNA display selection rounds needed to identify peptide binders
862 N. Guo et al. / EBioMedicine 2 (2015) 859–867compared to conventional mRNA display using a low-throughput
sequencing method.
3.2. mRNADisplay-HTS IdentiﬁesMotif Patterns ThatWere Not Detected by
Phage Display
We next performed mRNA display using a 27-mer library against
HCV mAb41, for which a previous phage display experiment identiﬁed
a WL binding motif that aligns with the W437 and L438 residues in the
wild type sequence pA of the HCV GT1a E2 protein (Duan et al., 2012).
We carried out four rounds of mRNA display selection and sequenced
the selected peptides by HTS after each round. The clone frequency dis-
tribution (Fig. 2A) indicated an increase in the abundance of certain
unique peptides after the 3rd round of selection, which followed a
pre-clearing step with protein G beads in the absence of the selection
antibody, indicating enrichment of these peptides. A fourth round of
selection further enriched the most common sequences selected in
the third round. Identiﬁed peptides were ranked by copy number
(Fig. 2B), and named based on their rank (with peptide p41_1 being
the most abundant peptide binder). The most abundant mRNA
display-enriched peptides show a W(L/I)XX(L/I) motif, which
aligns with W437, L438 and L441 residues in the wild type sequence. The
W(L/I) residues within the motif are similar to the WL identiﬁed by
previous phage display selection. Different from the phage display re-
sults, mRNA display often identiﬁed a second (L/I) residue within this
motif that aligns with L441 (Fig. 2B–C). Although the frequency of
W(L/I)XX(L/I) (2.54%, 57,925 reads containing W(L/I)XX(L/I) among
2,278,952 total reads) in the original 27mer library was a bit higher
than its expected frequency (1.65%) within a random library, due to
an unintentional bias towards inclusion of tryptophan-encoding codonsName
p41_1
p41_2
p41_3
p41_4
p41_5
p41_6
...
MQ
A B
C D
mAb
MMWWHED
MPWQ
MNMLGEDM
MDRPGPVFV
Library
97.44%
2.54%
0.02%
Peptide 
Peptide 
Fig. 2. Peptides identiﬁed bymRNA display-HTS using HCVmAb41. (A) Clone frequency distrib
1st to 4th rounds of selection. For each peptide pool obtained after one round of selection, sequ
11–100, 101–1000, 1001–10,000, and N10,000). The clone frequencies of the unique peptide seq
(2.3 × 106), 1st round (1.7 × 106), 2nd round (1.5 × 106), 3rd round (1.3 × 106), and 4th round
protein (aa 412–447) of HCV GT1a, and themost abundant peptides selected bymAb41 and the
are introduced to display sequence alignments. TheW(L/I)XX(L/I)motifs are in bold. Acidic resid
motif after each round of selection. (D) Peptides that show a perfect match to the wild type mo
number. (B) and (D) are among ~3.1 million total sequences obtained after 4th round of selecin the commercially prepared input library, a ~60% of selected pep-
tides from the 4th round of selection contained at least one copy of
W(L/I)XX(L/I) (Fig. 2C), indicating preferential selection of mAb41
for this motif.
Examination of all sequences with copy number exceeding 100
(~2000 the most abundant unique peptides) obtained from mRNA
display identiﬁed additional features including a preference for acidic
residues at theposition of theﬁrst X (Fig. 2B and Figure S2A) and theup-
stream G and downstream F residues (originally present in the wild
type sequence) in some selected peptides (Fig. 2B and Figure S2). No
other homology to the wild type E2 sequence was noted outside of
the GWLXXLF motif within the selected 27-mers (Fig. 2B). Similar
results were obtained when mRNA display selections against mAb41
were carried out using a 15-mer library, for which both W(L/I) and
W(L/I)XX(L/I) motifs were identiﬁed (Figure S3). The identiﬁcation of
two complete copies of theW(L/I)XX(L/I) motif using the 27mer library
most likely is due to its longer length, permitting inclusion of peptides
with more than one motif.
mRNA display-HTS of mAb41 also preferentially selected peptides
with tandem copies of the W(L/I) or W(L/I)XX(L/I) motifs (Fig. 2B–C
and Figure S3), a distinct feature that was not previously detected by
phage display. The downstream motif often overlapped the QLRNSCA
sequence that corresponds to the constant region of the mRNA display
peptides. For peptides selected using the 27-mer library, the percentage
of peptides containing tandem copies ofW(L/I)XX(L/I) motifs increased
over each selection round, especially after the 3rd round of selection,
when the percentage of the total number of peptides with the tandem
W(L/I)XX(L/I) motif increased thirty ﬁve-fold from 0.06% (881 reads
with tandem W(L/I)XX(L/I) among 1,455,481 total reads) in the 2nd
round to 2.11% (27,300 reads with tandem W(L/I)XX(L/I) amongMost abundant mAb41-selected peptides Copies
MMECEKGKYVQGWLCHLFWEDCQDRGWLEQLRNSCA
MRYEPMMMNCSPAWLQEIVQWLNEDWPEQLRNSCA
MTMPTMVEHSEVAWLDRLVTPYE---GWIECIQLRNSCA
MYMTSPMSQPCGWIEYLAHEDQPVP-WLDQLRNSCA
HWTQEYTTMWNEDTGWLDWLIEQDHCQLRNSCA
MWWHHTLMEKDDCWLDQLMADTERH-GWLEQLRNSCA
...
24137
18375
15745
14533
11107
9611
…
41-selected peptides containing the wild type motif Copies
QNGIRFRHSGEMAPGWLAGLFQLRNSCA
TLYKQQWMLTGYNRGWLAGLFAKDQLRNSCA
MERFKYTCHYGWLAGLFDIREEWLMSLTQLRNSCA
QVKKYFWFHDTCQQGWLAGLFQLRNSCA
MTADVLEVWPPTGWLAGLFMVVAQDDSEQLRNSCA
HGDGEQWFWNDIAEGWLAGLFQLRNSCA
…
5
3
2
2
2
1
…
A (pA): 412QLINTNGSWHINSTALNCNESLNTGWLAGLFYQHKF447
B (pB):                                     427LNCNESLNTGWLAGLFYQHK446
ution of the unique peptides with different copy numbers for the input 27-mer library, and
ences were ranked and divided into different groups based on their copy numbers (1–10,
uences in each groupwere calculated and graphed. The total readswere as follows: library
(3.1 × 106). (B) Sequences of thewild type peptide A (pA) and peptide B (pB) from the E2
ir copy numbers are listed. QLRNSCA is the constant region present in all peptides. Dashes
ues are italicized. (C) Frequencies of peptides containing 1 or 2 copies of theW(L/I)XX(L/I)
tif (GWLAGLF) were present among peptides selected by mAb41 but with far lower copy
tion.
863N. Guo et al. / EBioMedicine 2 (2015) 859–8671,292,412 total reads) in the 3rd round (Fig. 2C). Peptides with a single
copy of the wild type sequence (GWLAGLF) were also selected by
mAb41, but at much lower copy numbers (Fig. 2D), indicating a lower
degree of enrichment.
3.3. Selected Peptides Bind to the Selection Antibody mAb41 With
High Afﬁnity
The ﬁve most abundant selected peptides (p41-1 to p41-5, Fig. 2B)
were chemically synthesized for further analysis. By ELISA, mAb41
showed concentration-dependent binding to the mRNA display-
selected peptides (Fig. 3A). Peptide p41_1, the most abundant peptide
selected by mAb41, was used as a competitor of wild-type peptide B
(pB, a shorter version of pA, Fig. 2B) for binding to mAb41 to conﬁrm
that the selected peptides interact with the antigen-binding sites of
the selection antibody. Increasing amounts of p41_1 inhibited binding
of mAb41 to immobilized pB (Fig. 3B). This bindingwas not appreciably
affected by a negative control peptide from a mRNA display library
that is not enriched by mAb41 (Fig. 3B), implying that p41_1 binds to
the same antigen binding site on mAb41 as does wild type pB. Similar
results were obtained using p41_3 as competitor (Figure S4A). Using
the Octet binding assay, dissociation constants (Kd) of mAb41 Fabs
with mAb41-selected peptides (with the exception of p41_2 which
could not be evaluated due to unsatisfactory curve ﬁtting) were within
the 11–70 nanomolar range, similar to the afﬁnity of mAb41 Fab
fragments (Kd= 13 nM) for wild type pB (Fig. 3C–D and Figure S4B–E).
The acidic residues at the position of the ﬁrst X in most of the
W(L/I)XX(L/I) motifs were evaluated for their contribution to
mAb41 binding. By ELISA, an E to A mutation in the second W(L/
I)XX(L/I) motif of p41_1(WLEQL) modestly reduced mAb41 binding
afﬁnity as compared with peptide p41_1 (Figure S5A,B), whereas
substitution of an acidic residue in the corresponding position ofA B
DC
Peptid
p41_
p41_
p41_
p41_
pB
p41_1
0.0001 0.001 0.01 0.1 1 10 100
0.0
0.5
1.0
1.5
mAb41 concentration (ug/ml)
p41_1
p41_2
p41_3
p41_4
p41_5
Fig. 3. Binding of selected peptides to the selectionmAb41. (A) Binding of synthetic peptides to
microtiter plates.mAb41was applied as theprimary antibody in a 10-fold dilution series. HRP-c
themean of two replicates performed in one of three independent experiments, each ofwhich s
pB. 1 μg biotinylated pBwas attached to streptavidin-coated plates. 12 ng ofmAb41in 100 μl PBS
The boundmAb41was detected using anHRP-conjugated goat anti-mouse antibody. An unrela
graphed and error bars represent SEM of sample replicates. (C) Measurement of binding afﬁnit
Streptavidin biosensors (Fortebio) and Fabs of mAb41 were used as analyte in a 2-fold dilutio
(D) Binding constants of mAb41-selected peptides to mAb41 Fabs were obtained by ﬁtting se
not included due to unsatisfactory curve ﬁtting.p41_2 (a Q to E mutation in WLQEI) conferred an increased binding
afﬁnity (Figure S5A, C). Thus, this non-wild-type acidic residue likely
plays a role in peptide binding to mAb41.
3.4. mRNA Display-selected Peptides Can Elicit mAb41-like Binding and
Neutralizing Activity
Since the selected peptides bound mAb41 with high afﬁnity, we
hypothesized that these peptidesmightmimic native antigen in presen-
tation of critical epitopes to the immune system and thus might be
useful in inducing immune responses that resemble mAb41.We immu-
nized BALB/c mice (n = 4 or 5 for each immunogen) with the top ﬁve
peptides selected by mAb41. Polyclonal sera were named after the
immunizing peptides, i.e. anti-p41_1 is the serum obtained from mice
immunized with p41_1. Because mAb41 was cloned from mice previ-
ously immunized with pA peptide (Fig. 2B), we immunized mice with
the original wild type pA as a control. Polyclonal sera from immunized
mice showed binding reactivity to the immunizing peptides with titers
in the 1:104 to 105 range for most animals (Fig. 4A), with the exception
of p41_2, which showed lower titers (below 2 × 103) and were there-
fore excluded from further analysis. Since mAb41 speciﬁcally neutral-
izes HCV GT1a, we tested the capacity of these polyclonal sera to
neutralize HCV GT1a in vitro using 1a/2a chimeric HCVcc.
We screened antisera from mice immunized with each peptide
and found that polyclonal sera against mAb41 selected peptides
showed HCV GT1a neutralizing activity in a dose-dependent manner
(Figure S6A-D). All of themice immunizedwith themimotope peptides
developed neutralizing antibodies against the 1a/2a chimeric HCVcc.
The average neutralization titers (ID50) were 1:56 (anti-p41_1), 1:37
(anti-p41_3), 1:53 (anti-p41_4) and 1:43 (anti-p41_5), while naïve
mouse serum (NMS) had an undeterminable ID50 (b1:20) (Fig. 4B).
Only 2 out of 5 mice immunized with pA developed detectablees Kd (M) kon (1/Ms) kdis (1/s)
1 1.67E-08 1.44E+04 2.41E-04
3 3.29E-08 1.48E+04 4.87E-04
4 6.97E-08 1.06E+04 7.37E-04
5 1.10E-08 1.64E+04 1.81E-04
1.32E-08 1.05E+04 1.39E-04
mAb41 at various concentrations. Biotinylated peptideswere added to streptavidin-coated
onjugatedgoat anti-mouse antibodywasusedas thedetection antibody. Results shown are
howed similar results. (B) Competition for binding tomAb41 between p41_1 andwild type
containing 5%milkwas added in the presence of increasing amount of p41_1 as indicated.
ted peptide from themRNA display librarywas used as a negative control.Mean values are
y of selected peptides to mAb41 by Octet RED. Biotinylated peptides were immobilized on
n series ranging from 125 nM to 7.8 nM. Sensorgram data for peptide p41_1 are shown.
nsorgrams (blue) with a 1:1 model (red) using ForteBio Data Analysis Software. p41_2 is
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Figure S6E). To evaluate the speciﬁcity of the observed neutralizing
activity, anti-p41_1 sera were studied in depletion experiments. The
p41_1-speciﬁc binding activity was depleted to 25% of original levels
(p = 0.0077, as assessed by ELISA) from sera by adsorption to bead-
immobilized peptide p41_1 (Fig. 4C). The corresponding neutralizing
activity of the depleted sera was also reduced to 25% of original levels
(p = 0.002 compared to mock-depleted) when tested in cell culture
with 1a/2a chimeric HCVcc (Fig. 4D), indicating that the observed
neutralization was speciﬁc for the immunizing peptide.
To compare binding characteristics of peptide-elicited antibodies
with those of mAb41, we evaluated anti-p41_1 antisera, anti-pA
antisera, and mAb41 for their binding reactivity to pB and to the top
peptides selected by mAb41. Since peptides p41_1 to p41_5 were
enriched by mAb41 through multiple rounds of selection, as a group
they likely reﬂect the structure of the mAb41 antigen binding site and
thuswere used as signature peptides for detectingmAb41-like antibod-
ies. As expected, mAb41 bound to all the peptides in the ELISA (Fig. 5A).
Anti-p41_1 antisera showed a similar binding proﬁle to that of mAb41
when tested against the other mimotope peptides with the exception
of p41_2 (Fig. 5B). In contrast, anti-pA sera from the immunized mice
showed no detectable binding to any of the top 5 peptides selected by
mAb41 and only bound to pB (Fig. 5C). These results suggest that anti-
p41_1 sera contains mAb41-like antibodies, while in anti-pA sera, this
population is not dominant. Anti-p41_3 antisera showed a binding
proﬁle similar to that of anti-p41_1 (Fig. 5D). The reason for the differ-
ent behavior of p41_2 from that of other mAb41-selected peptides in
these assays remains unknown, but may be related to its relatively
low binding afﬁnity to mAb41 as assessed by ELISA (Fig. 3A).3.5. mRNA Display-HTS-selected Mimotopes Induce Mainly
Motif-speciﬁc Antibodies
To further characterize the binding properties of polyclonal antibod-
ies induced by mAb41-selected peptides, we assessed binding of poly-
clonal anti-p41_1 sera to a series of p41_1 mutant peptides (Fig. 6A).
Wemutated the key residues in the duplicatedWLXXL motif to alanine
either individually or in combination, and tested binding of anti-p41_1
antisera andmAb41 to thesemutant peptides. To evaluate the contribu-
tion of residues outside of the motif to the antibody response against
p41_1, we also designed a hybrid peptide (designated p41_1_ﬂag) in
which a GWLXXLF motif was preserved and other residues were
replaced by the FLAGTM epitope sequence (Fig. 6A). The overall binding
proﬁles to p41_1mutant peptideswere similar between anti-p41_1 and
mAb41 (Fig. 6B), further indicating that anti-p41_1 contains mAb41-
like antibodies. Both antibodies show signiﬁcantly reduced binding
to mutant peptides containing either the W13W27 mutations or the
L14L28 mutations. The L17 L31 mutations also resulted in amodest reduc-
tion in binding to both antibodies.Mutations of all themotif residues (as
indicated by peptide W13 L14 L17W27 L28 L31) resulted in almost com-
plete abrogation of binding to both antibodies to a level similar to the
signal obtainedwith NMS. p41_1 thus preferentially induced antibodies
to the speciﬁc WLXXL bindingmotifs and did not induce large amounts
of nonspeciﬁc antibodies to other residues or motifs present within
the peptide. The binding of mAb41 and anti-p41_1 to the p41_1_ﬂag
hybrid peptide remained strong (Fig. 6B), indicating that the residues
surrounding the GWLXXLF motifs are likely not contact residues in
antibody binding, and further indicating that the p41_1-induced anti-
bodies are mainly directed against the speciﬁc motifs. Anti-p41_1 and
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relative to p41_1, suggesting that the surrounding non-motif residues
contribute to an optimized presentation of the core motifs. Reduced
binding of antisera to the corresponding mutant peptides was also ob-
served for p41_3 and p41_4 when the WLXXL motifs were mutated
(Fig. 6A, C–D), indicating that the ability to induce a mAb41 epitope-
focused immune response is a common feature shared by the top pep-
tides selected by mAb41.
4. Discussion
The use of a high complexity selection library with massive data
output allowed mRNA display-HTS to unlock the intrinsic information
embedded in mAb antigen binding sites. Selected peptides identify
unique motif patterns, and as a whole, represent the binding speciﬁcity
of mAb41. The faithful capture of information intrinsic to the selection
mAb by the selected peptides was further manifested by the ability of
these peptides to induce antibodies that mimic both the epitope-
speciﬁc binding and the neutralizing activity of the original mAb. The
present ﬁndings support the general use of mRNA display-HTS as a
powerful approach in antigen identiﬁcation for reverse-engineering of
vaccines.
The high library complexity, afforded bymRNA display-HTS allowed
identiﬁcation of distinct features not identiﬁed in a previous phage
display experiment, including the preference for a tandem copy of the
W(L/I)XX(L/I) motif and acidic residues at certain positions. The impor-
tance of key residues for antibody interaction was conﬁrmed through
mutational analyses. The selection of peptides with a tandem copy of
the motif may be due to combined effects of high afﬁnity and avidity.
The increased avidity implied by selection of a duplicated pattern
might be related to interaction of two epitopemotifs with two adjacent
antigen binding sites of the selection antibody immobilized on the
protein G beads. The peptides selected within the mRNA displayexperiment showed in vitro afﬁnity for the monovalent mAb41 Fabs
similar to that of the wild-type sequence in the Octet binding assay,
even though the only common sequence among the peptides was the
W(L/I)XX(L/I) motif. This binding was strong for the peptides contain-
ing single (p41_5) or tandem W(L/I)XX(L/I) repeats (p41_1, p41-3
and p41_4). The Octet system, which used monovalent mAb41 Fabs,
may not have been capable of detecting a signiﬁcant increase in afﬁnity
for peptides with a second motif. These data conﬁrm that the presence
of this motif alone is sufﬁcient for high afﬁnity binding to the mAb41
and reinforces the application of the mRNA display technique for selec-
tion and analysis of antibody epitopes.
We studied themost abundant peptides in themRNAdisplay-HTS li-
brary for their ability to inducemAb41-like properties. p41_1 and p41_3
induced polyclonal serawithmAb41-like binding activity, preferentially
to the speciﬁc WLXXL binding motifs, more effectively than did the
original wild type pA. All antigen-antibody binding, including that of
antibody recognizing linear epitopes, involves a particular conformation
of the antigen. Since these peptides underwent several rounds of
afﬁnity-selection by mAb41, they (and other peptides selected by
mRNA display) likely possess complementarities optimized for the
mAb41 binding site, and thus may have a propensity to adopt a confor-
mation more closely resembling that of the native antigen in the E2
protein than does pA. Differences in solubility precluded comparison
of peptide secondary structure by circular dichroism; however, bioin-
formatic analysis using TASSER predicted alpha-helical structures in
the regions containing the W(L/I)XX(L/I) motif both of the mRNA
display-selected peptides and of pA (data not shown), It is unlikely
that disulﬁde bonds could have contributed to peptide secondary struc-
ture during the mRNA display selection because the preceding reverse
transcription step was performed in the presence of DTT.
We did not observe clear correlations between relativemAb41 bind-
ing afﬁnities of peptides as assessed by different methods (the mRNA
display selection, or in Octet or ELISA assays) and virus neutralization
secneuqeSsemaN
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among the binding interactions detected by these methods. However,
all methods indicated strong mAb41 binding of p41_1, p41_3, p41_4,
and p41_5. p41_2 showed both relatively lower mAb41 afﬁnity by
ELISA and weaker neutralizing immune responses. Improved neutraliz-
ing responses induced by mAb41-selected peptides than pA could also
be mediated by the duplicated W(L/I)XX(L/I) motif and/or the acidic
residues that allow a more favorable presentation of the epitope. It is
possible that pA presents the critical residues in a less favorablemanner
either due to the loss of optimal conformation when removed from its
native context (Fibriansah et al., 2014), or the lack of mAb41 preferred
features (duplicated W(L/I)XX(L/I) motif and acidic residues). This is
evidenced by the absence of detectable mAb41-like antibodies in anti-
pA polyclonal sera, despite the fact that this peptide was used for the
initial immunizations that resulted in the isolation of mAb41 (Duan
et al., 2012). These results suggest that mAb41 was a rare species in
the antibody pool originally induced by pA. Although some anti-pA
antisera showed GT1a neutralizing activity, this activity could have
beenmediated by non-mAb41-like antibodies, because pA also contains
other neutralizing epitopes (Duan et al., 2012). In contrast, p41_1 and
p41_3 induced a higher frequency of mAb41-like antibodies, targeting
speciﬁc residues within the critical motif, suggesting a more favorable
presentation of the WLXXL epitope than in pA. These results indicate
that mimotopes identiﬁed by mRNA display-HTS have potential as
improved vaccine antigens that shift the immune response towardsthe production of epitope-speciﬁc antibodies with desired activity,
achieving a result similar to that of other epitope-focused vaccine
design approaches (Correia et al., 2014). The mRNA display-HTS
approach could also be applied to identiﬁcation of linear mimetics for
mAbs against conformational epitopes. Due to the structural complexity
of conformational epitopes, linear peptidesmay not be able to recapitu-
late the full three dimensional structure of the original antigens. Using
more complex libraries (for example, of 80mer (Keefe and Szostak,
2001; Cho et al., 2000)) could help to address this limitation.
We chose to study mAb41 because it is a potent neutralizing
antibody that arises from an antigenic region that can induce both neu-
tralizing and non-neutralizing antibodies, providing a basis for investi-
gating whether mAb41 mimotopes could induce immune responses
with mAb41-like properties, including neutralization. MAb41-based
mimotopes by themselves may have limitations as HCV vaccines, due
to the genotype-speciﬁcity of mAb41 neutralization. Although peptides
are generally not considered ideal vaccine antigens, due to their ability
to adopt many conformations, we propose that such antigens have
potential utility as priming antigens to induce initial immune responses
with desired attributes, setting the stage for boosting with wild type
proteins or viral particles. mRNA display-selected peptides, carrying
information speciﬁc to neutralizing antibodies and the ability to direct
epitope-targeted immune responses, would potentially be more useful
as priming antigens than would wild type peptides. The magnitude
of the immune response observed after immunization of mice with
867N. Guo et al. / EBioMedicine 2 (2015) 859–867mAb41-selected peptides, is similar to that of some effective human
vaccines, even with a single epitope. While antibody titers needed to
protect against HCV infections are not known, neutralizing titers of
1:10 (or lower) are generally considered correlates of efﬁcacy for rubel-
la and measles vaccines (Hilleman et al., 1967). The magnitude of the
neutralizing titers induced after selected peptide immunization could
potentially be further improved using other antigen presentation tech-
niques (e.g., by addition of scaffold proteins or presentation of antigens
on the surface of virus-like particles) or adjuvants, or by using amixture
of mRNA-display-selected mimotopes to present multiple epitopes to
the immune system.
The present study shows that previously inaccessible information
encoded in mAbs can be unlocked using mRNA display, and demon-
strates the promise of mRNA display systems in antigenic characteriza-
tion in support of reverse-engineering of vaccines. In their totality,
peptides selected from a random library by mRNA display characterize
a mAb's binding speciﬁcity and provide information about antigens
that can induce polyclonal humoral immune responses that mimic the
originalmAb. This improved understandingofmAbs could lead to better
vaccine antigens, improved characterization of monoclonal antibody-
based products, and insights into the mechanism of action of monoclo-
nal antibodies (mAbs).
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